MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-23-2026
Medpace Holdings Operating Income 2011-2026 | MEDP
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Medpace Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 535 M | 447 M | 337 M | 279 M | 199 M | 167 M | 127 M | 101 M | 64.9 M | 52.5 M | 20.6 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 535 M | 20.6 M | 212 M |
Quarterly Operating Income Medpace Holdings
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 M | - | 142 M | 126 M | 114 M | - | 112 M | 105 M | 104 M | - | 84.9 M | 78.4 M | 86.2 M | - | 77.8 M | 60.2 M | 64.2 M | - | 53.7 M | 42.4 M | 47.6 M | - | 46.4 M | 30.1 M | 35.5 M | 36.1 M | 30 M | 35.3 M | 25.9 M | 30.7 M | 26.9 M | 23.3 M | 20.1 M | 15.4 M | 17.2 M | 16.3 M | 15.9 M | 12.9 M | 12.6 M | 14.1 M | 12.9 M | -889 K | 7.2 M | 7.87 M | 6.39 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 142 M | -889 K | 49.2 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Castle Biosciences
CSTL
|
-42.8 M | $ 19.24 | -22.26 % | $ 558 M |  USA |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.58 | -2.53 % | $ 175 M |  China |
 |
Agilent Technologies
A
|
1.35 B | $ 118.65 | 0.82 % | $ 36.1 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 21.44 | 2.39 % | $ 1.14 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.93 | 17.68 % | $ 2.57 M | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.09 | -0.49 % | $ 379 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 9.07 | 2.02 % | $ 1.16 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 18.73 | 4.87 % | $ 419 M | USA |
 |
Natera
NTRA
|
-541 M | $ 219.82 | 2.2 % | $ 21.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
1.42 B | $ 27.16 | -0.26 % | $ 25.8 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 181.68 | -0.03 % | $ 9 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 5.99 | -1.32 % | $ 355 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 15.11 | 1.27 % | $ 457 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 92.26 | 0.01 % | $ 11.6 B | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.95 | 0.02 % | $ 2.69 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 125.0 | 0.7 % | $ 10.3 B |  Irlanda |
 |
Illumina
ILMN
|
-833 M | $ 138.71 | -2.71 % | $ 22.1 B | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 5.36 | - | $ 224 M | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 2.0 | -5.22 % | $ 8.85 M | USA |
 |
Trinity Biotech plc
TRIB
|
-21.2 M | $ 0.59 | -1.99 % | $ 212 M | Irlanda |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 58.54 | -1.66 % | $ 3.5 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.19 | -0.68 % | $ 5.03 M | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 474.46 | 0.32 % | $ 179 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 91.0 | 5.63 % | $ 6.14 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 258.05 | 0.43 % | $ 21.5 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 130.71 | -6.26 % | $ 6.11 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.25 | 0.76 % | $ 2.01 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 190.84 | 0.9 % | $ 21.2 B | USA |
 |
Waters Corporation
WAT
|
271 M | $ 350.49 | 0.27 % | $ 20.9 B | USA |